- Eli Lilly said on Tuesday that the Food and Drug Administration has authorized a novel Alzheimer’s medication that has been demonstrated in clinical studies to somewhat delay the disease’s progression of memory loss and cognitive impairment.
- According to the company, the FDA approved the medication for use in persons with early-stage Alzheimer’s disease or moderate cognitive impairment. Kisunla functions by going after brain amyloid, which is thought to be a telltale sign of Alzheimer’s disease.
- The clearance is noteworthy, according to Mayo Clinic neurologist Dr. Ronald Petersen, since it offers an additional therapeutic alternative for the debilitating illness. Leqembi, a comparable medication, received full clearance from the FDA last summer.
According to Petersen, “It will give clinicians and patients a choice.”
- The Alzheimer’s Association estimates that 6.7 million Americans 65 years of age and older have Alzheimer’s in 2023. By 2060, the population is expected to rise to 13.8 million.
- Based on late-stage clinical research involving 1,700 participants, the government approved the medication because it delayed the development of Alzheimer’s by about 35% after 18 months when compared to a placebo. The clinical dementia rating scale, which evaluates a patient’s performance in six areas—memory, orientation, judgment and problem-solving, home and hobbies, and personal care—was used to quantify decline.
The results were similar to those obtained with Leqembi.
- Eli Lilly has said that it anticipates that patients will be permitted to discontinue the therapy after their levels of amyloid have dropped significantly. The likelihood of the amyloid returning is unknown, but if it does, the patient will probably need to resume therapy.
- Similar to other medications in its class, Kisunla may have potentially fatal adverse effects, such as brain hemorrhage and edema. The FDA reports that three fatalities were connected to the medicine, even though the majority of instances found in the study were minor.
- After Leqmebi, Kisunla is currently the second authorized medication for Alzheimer’s disease of its sort. Aduhelm, a medication manufactured by Biogen, was removed from the market earlier this year.
Treatment likely to be covered by Medicare
- Pat Bishara, a 79-year-old mother of three from Carmel, Indiana, took part in the extension experiment as well as the phase 3 trial when individuals who were first given a placebo were offered Kisunla.
- She enrolled in the experiment in the middle of 2021 after receiving a minor cognitive impairment diagnosis in late 2017.
- In addition to receiving the monthly injection, Bishara had routine psychological evaluations. On June 6, she got her last injection.
- According to Bishara, there were no obvious negative effects from the experiment. She admitted that most people may not even be aware that she had the illness, even though she sometimes has problems recalling people’s names. She says the therapy is to blame for it.
- “I have a gut feeling that if I hadn’t been taking something, I wouldn’t be doing as well as I am,” said Bishara.
According to Lilly, the price of a 12-month supply of Kisunla is $32,000.
- It is anticipated that Medicare will fund the medication. The Centers for Medicare and Medicaid Services said last year that it would cover newly approved FDA-approved medications for Alzheimer’s disease; however, clinicians will need to gather evidence on the medications’ real-world efficacy.
- The FDA had originally scheduled a decision about the therapy for March but postponed it to get more advice from its advisory group over whether the advantages exceeded the drawbacks.
- The drug’s clearance was recommended by the agency’s committee of outside experts last month, with a unanimous vote.
